PMID: 6990664Jan 1, 1980Paper

Evaluation of the antiarrhythmic efficacy of mexiletine in patients with chronic ventricular arrhythmias

Acta cardiologica. Supplementum
J P Van Durme

Abstract

For the evaluation of arrhythmias and the assessment of antiarrhythmic therapy prolonged periods of recording, as provided by the Holter system, are needed. The 12 lead electrocardiogram and rhythm strips are unsuitable for these purposes. However an exercise test may provide useful additional information. In two trials mexiletine was compared with other antiarrhythmic drugs (atenolol, disopyramide, lorcainide) and placebo. In both trials mexiletine was shown to have a good antiarrhythmic efficacy on chronic ventricular premature beats. The high incidence of side-effects was probably due to the high dosage used.

Related Concepts

Related Feeds

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.